1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Pezolerocept Consumption Value by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 450 mg/7.5 mL
  • 1.3.3 150 mg/mL
• 1.4 Market Analysis by Route of Administration
  • 1.4.1 Overview: Global Pezolerocept Consumption Value by Route of Administration: 2021 Versus 2025 Versus 2032
  • 1.4.2 Intravenous Infusion
  • 1.4.3 Subcutaneous Injection
• 1.5 Market Analysis by Combination Therapy
  • 1.5.1 Overview: Global Pezolerocept Consumption Value by Combination Therapy: 2021 Versus 2025 Versus 2032
  • 1.5.2 Combined With Conventional Immunosuppressive Agents
  • 1.5.3 Combined With Topical Glucocorticoids
• 1.6 Market Analysis by Sales Channels
  • 1.6.1 Overview: Global Pezolerocept Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
  • 1.6.2 Hospital
  • 1.6.3 Retail
  • 1.6.4 Online
• 1.7 Market Analysis by Application
  • 1.7.1 Overview: Global Pezolerocept Consumption Value by Application: 2021 Versus 2025 Versus 2032
  • 1.7.2 Treatment Of Generalized Pustular Psoriasis
  • 1.7.3 Treatment Of Palmoplantar Pustulosis
  • 1.7.4 Treatment Of IL-36 Mediated Autoinflammatory Skin Diseases
  • 1.7.5 Others
• 1.8 Global Pezolerocept Market Size & Forecast
  • 1.8.1 Global Pezolerocept Consumption Value (2021 & 2025 & 2032)
  • 1.8.2 Global Pezolerocept Sales Quantity (2021-2032)
  • 1.8.3 Global Pezolerocept Average Price (2021-2032)

2 Manufacturers Profiles

• 2.1 Boehringer Ingelheim
  • 2.1.1 Boehringer Ingelheim Details
  • 2.1.2 Boehringer Ingelheim Major Business
  • 2.1.3 Boehringer Ingelheim Pezolerocept Product and Services
  • 2.1.4 Boehringer Ingelheim Pezolerocept Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 Boehringer Ingelheim Recent Developments/Updates

3 Competitive Environment: Pezolerocept by Manufacturer

• 3.1 Global Pezolerocept Sales Quantity by Manufacturer (2021-2026)
• 3.2 Global Pezolerocept Revenue by Manufacturer (2021-2026)
• 3.3 Global Pezolerocept Average Price by Manufacturer (2021-2026)
• 3.4 Market Share Analysis (2025)
  • 3.4.1 Producer Shipments of Pezolerocept by Manufacturer Revenue ($MM) and Market Share (%): 2025
  • 3.4.2 Top 3 Pezolerocept Manufacturer Market Share in 2025
  • 3.4.3 Top 6 Pezolerocept Manufacturer Market Share in 2025
• 3.5 Pezolerocept Market: Overall Company Footprint Analysis
  • 3.5.1 Pezolerocept Market: Region Footprint
  • 3.5.2 Pezolerocept Market: Company Product Type Footprint
  • 3.5.3 Pezolerocept Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Pezolerocept Market Size by Region
  • 4.1.1 Global Pezolerocept Sales Quantity by Region (2021-2032)
  • 4.1.2 Global Pezolerocept Consumption Value by Region (2021-2032)
  • 4.1.3 Global Pezolerocept Average Price by Region (2021-2032)
• 4.2 North America Pezolerocept Consumption Value (2021-2032)
• 4.3 Europe Pezolerocept Consumption Value (2021-2032)
• 4.4 Asia-Pacific Pezolerocept Consumption Value (2021-2032)
• 4.5 South America Pezolerocept Consumption Value (2021-2032)
• 4.6 Middle East & Africa Pezolerocept Consumption Value (2021-2032)

5 Market Segment by Type

• 5.1 Global Pezolerocept Sales Quantity by Type (2021-2032)
• 5.2 Global Pezolerocept Consumption Value by Type (2021-2032)
• 5.3 Global Pezolerocept Average Price by Type (2021-2032)

6 Market Segment by Application

• 6.1 Global Pezolerocept Sales Quantity by Application (2021-2032)
• 6.2 Global Pezolerocept Consumption Value by Application (2021-2032)
• 6.3 Global Pezolerocept Average Price by Application (2021-2032)

7 North America

• 7.1 North America Pezolerocept Sales Quantity by Type (2021-2032)
• 7.2 North America Pezolerocept Sales Quantity by Application (2021-2032)
• 7.3 North America Pezolerocept Market Size by Country
  • 7.3.1 North America Pezolerocept Sales Quantity by Country (2021-2032)
  • 7.3.2 North America Pezolerocept Consumption Value by Country (2021-2032)
  • 7.3.3 United States Market Size and Forecast (2021-2032)
  • 7.3.4 Canada Market Size and Forecast (2021-2032)
  • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

• 8.1 Europe Pezolerocept Sales Quantity by Type (2021-2032)
• 8.2 Europe Pezolerocept Sales Quantity by Application (2021-2032)
• 8.3 Europe Pezolerocept Market Size by Country
  • 8.3.1 Europe Pezolerocept Sales Quantity by Country (2021-2032)
  • 8.3.2 Europe Pezolerocept Consumption Value by Country (2021-2032)
  • 8.3.3 Germany Market Size and Forecast (2021-2032)
  • 8.3.4 France Market Size and Forecast (2021-2032)
  • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
  • 8.3.6 Russia Market Size and Forecast (2021-2032)
  • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

• 9.1 Asia-Pacific Pezolerocept Sales Quantity by Type (2021-2032)
• 9.2 Asia-Pacific Pezolerocept Sales Quantity by Application (2021-2032)
• 9.3 Asia-Pacific Pezolerocept Market Size by Region
  • 9.3.1 Asia-Pacific Pezolerocept Sales Quantity by Region (2021-2032)
  • 9.3.2 Asia-Pacific Pezolerocept Consumption Value by Region (2021-2032)
  • 9.3.3 China Market Size and Forecast (2021-2032)
  • 9.3.4 Japan Market Size and Forecast (2021-2032)
  • 9.3.5 South Korea Market Size and Forecast (2021-2032)
  • 9.3.6 India Market Size and Forecast (2021-2032)
  • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
  • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

• 10.1 South America Pezolerocept Sales Quantity by Type (2021-2032)
• 10.2 South America Pezolerocept Sales Quantity by Application (2021-2032)
• 10.3 South America Pezolerocept Market Size by Country
  • 10.3.1 South America Pezolerocept Sales Quantity by Country (2021-2032)
  • 10.3.2 South America Pezolerocept Consumption Value by Country (2021-2032)
  • 10.3.3 Brazil Market Size and Forecast (2021-2032)
  • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

• 11.1 Middle East & Africa Pezolerocept Sales Quantity by Type (2021-2032)
• 11.2 Middle East & Africa Pezolerocept Sales Quantity by Application (2021-2032)
• 11.3 Middle East & Africa Pezolerocept Market Size by Country
  • 11.3.1 Middle East & Africa Pezolerocept Sales Quantity by Country (2021-2032)
  • 11.3.2 Middle East & Africa Pezolerocept Consumption Value by Country (2021-2032)
  • 11.3.3 Turkey Market Size and Forecast (2021-2032)
  • 11.3.4 Egypt Market Size and Forecast (2021-2032)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
  • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

• 12.1 Pezolerocept Market Drivers
• 12.2 Pezolerocept Market Restraints
• 12.3 Pezolerocept Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Pezolerocept and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Pezolerocept
• 13.3 Pezolerocept Production Process
• 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Pezolerocept Typical Distributors
• 14.3 Pezolerocept Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Pezolerocept market size was valued at US$ 87.46 million in 2025 and is forecast to a readjusted size of US$ 449 million by 2032 with a CAGR of 12.1% during review period.
Spesolimab is a humanized monoclonal antibody targeting the interleukin-36 receptor (IL-36R), a targeted immunological biologic agent. It specifically binds to and blocks the IL-36 receptor signaling pathway to suppress excessive inflammatory responses in the skin and related tissues. Primarily indicated for the treatment of autoinflammatory skin diseases such as generalized pustular psoriasis, it represents a precision-targeted therapy against the pathogenesis of pustular psoriasis, characterized by rapid onset and high specificity in clinical practice.In 2025, global Spesolimab production reached approximately 18,000–22,000 vials
Spesolimab, the world’s first IL-36 receptor-targeted biologic exclusively developed for generalized pustular psoriasis (GPP), holds a first-in-class monopoly in the global rare dermatology market by addressing a long-standing unmet medical need with its precise mechanism that blocks the core inflammatory pathway and rapidly controls life-threatening symptoms. Approved in over 40 countries and regions worldwide, its global commercialization has been fully transferred to LEO Pharma, which leverages its specialized dermatology platform and global network to enhance disease awareness and treatment access. Positioned as a high-value orphan drug, it adopts a premium pricing strategy supported by strong clinical evidence; despite a limited patient population, it benefits from a clear competitive landscape with no direct same-target competitors, and its long-term growth hinges on indication expansion, approval of subcutaneous maintenance therapy, and broader insurance coverage. Characterized by a niche but essential market, specialty-driven promotion, global footprint, and indication-led expansion, spesolimab is poised to unlock broader potential in IL-36-mediated autoinflammatory skin disorders as research and clinical adoption advance.
This report is a detailed and comprehensive analysis for global Pezolerocept market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Pezolerocept market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Pezolerocept market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Pezolerocept market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Pezolerocept market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Pezolerocept
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Pezolerocept market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Boehringer Ingelheim, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Pezolerocept market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
450 mg/7.5 mL
150 mg/mL
Market segment by Route of Administration
Intravenous Infusion
Subcutaneous Injection
Market segment by Combination Therapy
Combined With Conventional Immunosuppressive Agents
Combined With Topical Glucocorticoids
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Application
Treatment Of Generalized Pustular Psoriasis
Treatment Of Palmoplantar Pustulosis
Treatment Of IL-36 Mediated Autoinflammatory Skin Diseases
Others
Major players covered
Boehringer Ingelheim
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Pezolerocept product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Pezolerocept, with price, sales quantity, revenue, and global market share of Pezolerocept from 2021 to 2026.
Chapter 3, the Pezolerocept competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Pezolerocept breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Pezolerocept market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Pezolerocept.
Chapter 14 and 15, to describe Pezolerocept sales channel, distributors, customers, research findings and conclusion.